This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
This technical report presents considerations for European Union/European Economic Area (EU/EEA) countries when diagnosing barriers to acceptance and uptake of COVID-19 vaccination, and designing and implementing interventions to increase uptake.
This study provides insights for national public health authorities into the factors behind the spread of vaccine misinformation online and the options and capacities needed for responding to it.
The purpose of this document is to address the safety of donors and products involving Substances of Human Origin (SoHO) and the potential risk of thrombosis with thrombocytopenia adverse events following COVID-19 vaccination of a donor.
This Technical Report presents evidence about the current status of Behavioural Insights (BI) research being conducted in the ten EU/EEA Member States that responded to an ECDC survey, within the context of the COVID-19 pandemic.
The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.